Planview Announces Record Q2’21 and First Half
Planview, a global leader in Portfolio Management and Work Management solutions, today reported record revenue and bookings in Q2 2021 continuing a trend of strong momentum and growth in 2021. Bookings for the second quarter of the year were at a record high, and total bookings in the first half of 2021 increased 40 percent year-over-year on a consolidated basis. The bookings growth in the second quarter of 2021 was driven by both new customer additions and customer expansions across financial services, pharmaceutical, and manufacturing industries. Additionally, total software annual recurring revenue (ARR) for Q2 increased to an all-time high in excess of $300 million.
“Our customers are grappling with change across multiple vectors: from evolving market dynamics, fierce competition, and changing customer expectations, to new business models, shifting company strategies and entirely new ways of working,” said Razat Gaurav, chief executive officer, Planview. “The key to turning these changes into opportunities is a company’s ability to adapt, be agile, and constantly transform. Planview’s Portfolio and Work Management solutions enable customers to embrace change without losing sight of key priorities or company strategy.”
Q2 2021 Customer Momentum
Planview’s momentum in Q2 has been driven by key customer wins and expansions. Throughout the quarter, the company added 112 net new customers, reaching a total of 225 net new customers in 2021. Customers who selected or extended their footprint with Planview during the quarter include: Global Payments, KBI Biopharma, Lonza, and Rosenberger Hochfrequenztechnik GmbH & Co.
“KBI Biopharma prides itself on high technical standards and scientific rigor, and our ability to tailor our contract development and manufacturing organization (CDMO) offerings to meet the individual needs of each and every partner,” said Dirk Lange, President and CEO, KBI Biopharma. “We chose to invest in Planview software because it enables the precision and insight that we need to optimally structure and resource our client engagements. We are looking forward to our continued growth with the support of this platform to help advance lifesaving therapeutics to patients in need.”
- Louise K. Allen, Chief Product Officer
- Todd Watts, Chief Customer Officer
- Matt Zilli, Chief Revenue Officer
- Cameron van Orman, Chief Strategy & Marketing Officer
- Jay Nelson, Chief People Officer
- Beth Weeks, Chief Information Officer and Vice President, Cloud Operations
- Rob Reesor, Chief Technology Officer and SVP, Product Development
- Chris Carsen, Chief Legal Officer
“I’m excited to support this world-class leadership team as we scale up our business,” said Gaurav. “Our opportunity to enable digital transformation and reimagine the future of connected work in the enterprise is now. We can only fulfill this massive value potential by continuing to be very committed to our core values underpinned by product innovations, customer and employee success.”
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK2.8.2021 09:00:00 CEST | Press release
Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005278/en/ Artist Impression No. 1 (Photo: Business Wire) Funds managed by Blackstone Real Estate Partners and Hudson Pacific Properties acquired a 91-acre site, 17 miles north of central London, through a joint venture for £120 million. The acquisition, with an expected total investment of over £700 million, will be the partners’ first expansion of their Sunset Studios platform outside of the US. The proposed development, which is subject to planning permission, would transform the site into one of the largest world-class film and television studio campuses. The project is expected to create over 4,500 permanent jobs for Broxbourne and the surrounding community and contribute more than £300 million annually int
AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies2.8.2021 08:00:00 CEST | Press release
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. „I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, A
Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract2.8.2021 08:00:00 CEST | Press release
Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America. Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospi
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders2.8.2021 07:00:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210801005028/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.1 Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.1,2 Exicure’s SNAs provide distinct chemical and biochemical properties to oligonucleotides. I
Arqit Releases QuantumCloud™ to Deliver Stronger, Simpler Encryption2.8.2021 06:20:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology announces the release of the first version of its service, QuantumCloud™ 1.0. This Platform‑as‑a‑Service software enables customers to secure the communications channels and data of any cloud, edge or end-point device. The service combines transformational and unique advances in both quantum and classical cryptography. The release of QuantumCloud™ 1.0 allows customers to secure devices globally by providing a strong device authentication capability, over which is layered the agreement of symmetric keys between authenticated and authorised devices. Importantly, since there are no asymmetric cryptographic primitives used within the trustless key agreement protocol, the keys can be regarded as safe against future attack using Shor’s algorithm running on a quantum computer. A range of other features will be added in future quarters, culminating in the launch of Arqit’s proprietary quantum satellites, which is targeted for 2
Arqit Registration Statement Related to Business Combination With Centricus Acquisition Corp. Declared Effective By SEC2.8.2021 06:04:00 CEST | Press release
Arqit Limited (“Arqit”), a leader in quantum encryption technology today announced the Registration Statement on Form F-4 in connection with the previously announced business combination (the “Business Combination”) with Centricus Acquisition Corp. (“Centricus”) (Nasdaq: CENHU, CENH, CENHUW), a publicly-listed special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (the “SEC”). Upon closing, the ordinary shares and warrants of Arqit Quantum Inc., a company formed for purposes of completing the Business Combination, will be listed on NASDAQ under the new ticker symbols “ARQQ” and “ARQQW.” The boards of directors of Arqit and Centricus have unanimously approved the Business Combination, and Centricus has set 9:00 a.m. ET on August 31, 2021 as the time and date for an extraordinary general meeting of shareholders to approve the proposals associated with the Business Combination. The proxy statement/prospectus contains important informatio
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie2.8.2021 01:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means including appealing the decision to the Irish courts. On November 28, 2018, Shire received a tax assessment from the Irish Revenue Commissioners for 398 million EUR. This assessment sought to tax a 1,635 million USD break fee Shire received from AbbVie in connection with the terminated offer to acquire Shire made by AbbVie in 2014. Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission. While Takeda is continuing to assess the substance of the decision, the company will record a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom